COMMUNIQUÉS West-GlobeNewswire

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma
11/11/2025
225Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers BERLIN, Nov. 11, 2025 ( [...]
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
11/11/2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an [...]
Canadian Red Cross sending emergency medical clinic to Jamaica
11/11/2025
Humanitarian experts deploying to help people impacted by Hurricane Melissa OTTAWA, Ontario, Nov. 10, 2025 (GLOBE NEWSWIRE) -- In response to the devastating impact of Hurricane Melissa across the Caribbean region, the [...]
La Croix-Rouge canadienne déploie une clinique médicale d’urgence en Jamaïque
11/11/2025
Des spécialistes humanitaires sont mobilisés pour porter secours aux personnes touchées par l’ouragan Melissa OTTAWA, Ontario, 10 nov. 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne, en collaboration avec la [...]
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
11/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11/2025
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Burn Blend 2025 | Effective Weight Loss Supplement Read Benefits, Ingredients Lunch Burn Blend Canada & Australia
10/11/2025
Burn Blend is a natural Weight Loss Supplement that combines nature’s most effective ingredients to support focus, endurance, and metabolism. Read BurnBlend consumer reports. New York City, Nov. 10, 2025 (GLOBE NEWSWIRE [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Third Quarter 2025 Financial Results on November 14, 2025
10/11/2025
FREDERICK, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
10/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)- [...]
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/11/2025
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
10/11/2025
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required [...]
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
10/11/2025
Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents [...]
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
10/11/2025
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high [...]
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
10/11/2025
Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and [...]
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
10/11/2025
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA [...]
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
10/11/2025
Delivered ~ 21% worldwide revenue growth, ~ 5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) [...]
Oculis Reports Q3 2025 Financial Results and Provides Company Update
10/11/2025
ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic [...]
Oculis Reports Q3 2025 Financial Results and Provides Company Update
10/11/2025
Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA [...]
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
10/11/2025
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – [...]

Pages